Abstract
Objectives: Myoglobin provides the earliest indication of acute myocardial infarction. In this study, the new myoglobin assay for the VIDAS system (bioMérieux) was evaluated. Design and methods: This assay, using an enzyme-linked fluorescent immunoassay (ELFIA) method, was compared with the Olympus R immunoturbidimetric method and with another immunometric method (Immulite turbo R) using an enzyme-linked chemiluminescent immunoassay (CLIA). Results: The CVs for within-and between-run reproducibility are very similar for the tested methods and acceptable linearity ranges were obtained. No significant interference of hemolysis, turbidity and icteria was observed. In the whole cohort, we obtained decreased values over the entire range of the assay with VIDAS and Immulite turbo methods compared to the Olympus assay; this is probably mainly linked to differences in standards used due to the absence of international standardization of the myoglobin determination. Conclusions: The new VIDAS myoglobin automated assay provides biologists with a rapid, accurate and reliable determination of myoglobin in plasma samples collected during cardiac workup.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call